Patients with multiple sclerosis (MS) who initiated treatment with subcutaneous interferon beta-1a (scIFNβ1a) were less likely to experience a relapse in the first year than those who initiated treatment with oral disease-modifying drugs (DMDs).
Results of the study were presented at the 2016 CMSC Annual Meeting in National Harbor, MD.
In order to evaluate relapse rates in a real-world population, researchers led by Chris M. Kozma identified 1665 patients (mean age= 44.4 years; 75.5% female) with MS from the IMS LifeLink PharMetrics Plus Database between January 1, 2012 and June 30, 2013. Relapse was assessed at 12 months and defined as MS-related hospitalization, MS-related emergency room visit, or MS-related outpatient visit with corticosteroid prescription.
In all, 686 patients initiated scIFNβ1a, 118 initiated teriflunomide, 455 initiated fingolimod, and 406 initiated dimethyl fumarate. Unadjusted analysis showed no difference in MS-related hospitalizations or ER visits among all DMDs, however fewer patients initiating scIFNβ1a experienced an MS-related outpatient relapse (19.7%) compared to those initiating teriflunomide (32.3%; P=.003) or dimethyl fumarate (26.8%; P=.006). The proportion of patients with any type of MS relapse was lower in those initiating scIFNβ1a (21.7%) compared to oral DMDs (26.1%; P=.039). After controlling for demographics and 90-day pre-index indicators of disease severity, logistic regression analysis showed a greater risk of relapse when teriflunomide or demethyl fumurate were initiated (odds ratio [OR] = 2.1; P = .001 and OR = 1.5; P = .005, respectively) vs scIFNβ1a. Additionally, a neurologist visit (P=.034) and MS relapse (P<.0001) 90 days before treatment initiation was associated with relapse.
Overall, the results indicate that patients initiating scIFNβ1a have a lower likelihood of experiencing MS relapse than patients initiating teriflunomide or dimethyl fumarate.
Disclosures: Chris M. Kozma: EMD Serono, Inc (grant/research support); Frederick Munschauer, Amy L. Phillips: EMD Serono, Inc (employee).
Kozma CM, Munschauer F, Phillips AL. Abstract DX35. Relapse Rates of Patients with Multiple Sclerosis Newly Initiating Subcutaneous Interferon Beta-1a Versus Oral Disease-Modifying Drugs in the Real World. Presented at: 2016 CMSC Annual Meeting. June 1-4, 2016; National Harbor, MD.